News
-
-
-
-
-
-
PRESS RELEASE
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
Protagonist Therapeutics announces development candidate PN-477, a triple agonist peptide, targeting GLP-1, GIP, GCG receptors for obesity treatment. IND-enabling studies in progress, Phase I initiation expected in 2Q26 -
PRESS RELEASE
aap Implantate AG closes financial year 2024 successfully - positive developments despite challenging environment
aap Implantate AG successfully closes financial year 2024 with positive developments, achieving sales growth and strengthening market position, especially in EMEA and LATAM regions -
PRESS RELEASE
Sanofi: Disclosure of trading in own shares
-
-
PRESS RELEASE
EQS-Adhoc: HomeToGo Now Guides on Standalone Basis Due to Confirmed Delayed Closing of Interhome Acquisition - Mid-term Growth Trajectory Fully Intact
HomeToGo SE adjusts financial guidance for FY/25 due to delayed closing of Interhome acquisition, now guiding on standalone basis. Mid-term growth trajectory remains intact
